Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF

Biochemical Pharmacology

Volumn 60, Issue 9, 2000, Pages 1305-1313

  Ferry, Katherine V ^a,b   Hamilton, Thomas C ^a   Johnson, Steven W ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b LEHIGH UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cisplatin; Drug resistance; ERCC1; Nucleotide excision repair; Ovarian cancer; XPF

Indexed keywords

CISPLATIN;

ARTICLE; CYTOTOXICITY; DNA DAMAGE; EXCISION REPAIR; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMAN; OVARIAN NEOPLASMS; PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0034333419     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00441-X     Document Type: Article

References (43)

1. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin Oncol. 25:1998;340-348.
2. O'Dwyer PJ, Hamilton TC and Johnson SW, Cisplatin and its analogues. In: Principles and Practice of Oncology (Ed. DeVita VJ), 418-432. J.B. Lippincott, Philadelphia, 1997.
3. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 34:1987;155-166.
4. Plooy A.C., Fichtinger-Schepman A.M., Schutte H.H., van Dijk M., Lohman P.H. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin Application of immunochemical techniques . Carcinogenesis. 6:1985;561-566.
5. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Lohman P.H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA Formation, identification, and quantitation . Biochemistry. 24:1985;707-713.
6. Andrews P.A., Velury S., Mann S.C., Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48:1988;68-73.
7. Kuppen P.J., Schuitemaker H., van't Veer L.J., de Bruijn E.A., van Oosterom A.T., Schrier P.I. cis-Diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cells. Cancer Res. 48:1988;3355-3359.
8. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 52:1992;3857-3864.
9. Schilder R.J., Hall L., Monks A., Handel L.M., Fornace A.J. Jr, Ozols R.F., Fojo A.T., Hamilton T.C. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer. 45:1990;416-422.
10. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., Ozols R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:1987;414-418.
11. Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 64:1991;215-220.
12. Hamilton T.C., Winker M.A., Louie K.G., Batist G., Behrens B.C., Tsuruo T., Grotzinger K.R., McKoy W.M., Young R.C., Ozols R.F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 34:1985;2583-2586.
13. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 89:1992;3070-3074.
14. Masuda H., Ozols R.F., Lai G.-M., Fojo A., Rothenberg M., Hamilton T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res. 48:1988;5713-5716.
15. Lai G.-M., Ozols R.F., Smyth J.F., Young R.C., Hamilton T.C. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol. 37:1988;4597-4600.
16. Masuda H., Tanaka T., Matsuda H., Kusaba I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 50:1990;1863-1866.
17. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 87:1991;772-777.
18. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F., Hamilton T.C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol. 47:1994;689-697.
19. Zhen W., Link C.J. Jr, O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 12:1992;3689-3698.
20. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57:1997;850-856.
21. Hamaguchi K., Godwin A.K., Yakushiji M., O'Dwyer P.J., Ozols R.F., Hamilton T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53:1993;5225-5232.
22. Johnson S.W., Swiggard P.A., Handel L.M., Brennan J.M., Godwin A.K., Ozols R.F., Hamilton T.C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 54:1994;5911-5916.
23. Wood R.D. Nucleotide excision repair in mammalian cells. J Biol Chem. 272:1997;23465-23468.
24. Moggs J.G., Yarema K.J., Essigmann J.M., Wood R.D. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem. 271:1996;7177-7186.
25. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 119:1989;203-210.
26. Manley J.L., Fire A., Cano A., Sharp P.A., Gefter M.L. DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract. Proc Natl Acad Sci USA. 77:1980;3855-3859.
27. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry. 35:1996;10004-10013.
28. Perez R.P., Godwin A.K., Handel L.M., Hamilton T.C. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer. 29A:1993;395-399.
29. Aboussekhra A., Wood R.D. Repair of UV-damaged DNA by mammalian cells and Saccharomyces cerevisiae. Curr Opin Genet Dev. 4:1994;212-220.
30. Park C.-H., Bessho T., Matsunaga T., Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem. 270:1995;22657-22660.
31. Sijbers A.M., van der Spek P.J., Odijk H., van den Berg J., van Duin M., Westerveld A., Jaspers N.G., Bootsma D., Hoeijmakers J.H. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res. 24:1996;3370-3380.
32. Bessho T., Sancar A., Thompson L.H., Thelen M.P. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem. 272:1997;3833-3837.
33. Evans E., Moggs J.G., Hwang J.R., Egly J.M., Wood R.D. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 16:1997;6559-6573.
34. Andersson B.S., Sadeghi T., Siciliano M.J., Legerski R., Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol. 38:1996;406-416.
35. Saijo M., Kuraoka I., Masutani C., Hanaoka F., Tanaka K. Sequential binding of DNA repair proteins RPA and ERCC1 to XPA in vitro. Nucleic Acids Res. 24:1996;4719-4724.
36. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 94:1994;703-708.
37. Li Q., Tsang B., Bostick-Bruton F., Reed E. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol. 57:1999;347-353.
38. Yao K.-S., Godwin A.K., Johnson S.W., Ozols R.F., O'Dwyer P.J., Hamilton T.C. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 55:1995;4367-4374.
39. Koberle B., Grimaldi K.A., Sunters A., Hartley J.A., Kelland L.R., Masters J.R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer. 70:1997;551-555.
40. Zeng-Rong N., Paterson J., Alpert L., Tsao M.-S., Viallet J., Alaoui-Jamali M.A. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 55:1995;4760-4764.
41. Yen L., Woo A., Christopoulopoulos G., Batist G., Panasci L., Roy R., Mitra S., Alaoui-Jamali M.A. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Mutat Res. 337:1995;179-189.
42. Ali-Osman F., Berger M.S., Rairkar A., Stein D.E. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases α and β, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem. 54:1994;11-19.
43. Petersen L.N., Mamenta E.L., Stevnsner T., Chaney S.G., Bohr V.A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis. 17:1996;2597-2602.